First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a …

Y Liu, H Yue, S Xu, F Wang, N Ma, K Li, L Qiao… - International journal of …, 2015 - Springer
Background Because of the poor prognosis of unresectable or metastatic hepatocellular
carcinoma there is a need for effective systemic therapy. The purpose of this study was to …
被引用次数：34 相关文章

First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a …

Y Liu, H Yue, S Xu, F Wang, N Ma, K Li, L Qiao… - International Journal of …, 2015 - infona.pl
Background Because of the poor prognosis of unresectable or metastatic hepatocellular
carcinoma there is a need for effective systemic therapy. The purpose of this study was to …

First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a …

Y Liu, H Yue, S Xu, F Wang, N Ma, K Li… - … Journal of Clinical …, 2015 - search.proquest.com
Background Because of the poor prognosis of unresectable or metastatic hepatocellular
carcinoma there is a need for effective systemic therapy. The purpose of this study was to …

First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a …

Y Liu, H Yue, S Xu, F Wang, N Ma, K Li… - International Journal of …, 2015 - hero.epa.gov
BACKGROUND: Because of the poor prognosis of unresectable or metastatic hepatocellular
carcinoma there is a need for effective systemic therapy. The purpose of this study was to …

First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a …

Y Liu, H Yue, S Xu, F Wang, N Ma, K Li… - … Journal of Clinical …, 2015 - search.ebscohost.com
Background: Because of the poor prognosis of unresectable or metastatic hepatocellular
carcinoma there is a need for effective systemic therapy. The purpose of this study was to …

First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a …

Y Liu, H Yue, S Xu, F Wang, N Ma… - … journal of clinical …, 2015 - pubmed.ncbi.nlm.nih.gov
Background Because of the poor prognosis of unresectable or metastatic hepatocellular
carcinoma there is a need for effective systemic therapy. The purpose of this study was to …

First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a …

Y Liu, H Yue, S Xu, F Wang, N Ma, K Li… - … Journal of Clinical …, 2015 - europepmc.org
Background Because of the poor prognosis of unresectable or metastatic hepatocellular
carcinoma there is a need for effective systemic therapy. The purpose of this study was to …

[引用][C] First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular …

Y Liu, H Yue, S Xu, F Wang, N Ma, K Li, L Qiao… - International Journal of …, 2015 - cir.nii.ac.jp
First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as
maintenance therapy, for patients with advanced hepatocellular carcinoma: a preliminary study …

[引用][C] First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular …

Y Liu, H Yue, S Xu, F Wang, N Ma, K Li, L Qiao… - International journal of …, 2015 - Springer